Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction

Eisuke Suganuma, Yiqin Zuo, Nobuhiko Ayabe, Ji Ma, Vladimir R. Babaev, MacRae F. Linton, Sergio Fazio, Iekuni Ichikawa, Agnes B. Fogo, Valentina Kon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Angiotensin II (Ang II) increases atherosclerotic cardiovascular disease. Renal damage that is characterized by activation of Ang II markedly potentiates the risk for atherosclerosis, even in the setting of subtle renal impairment. Therefore, whether antagonism of Ang II actions can modify atherosclerosis in a model of mild renal impairment was examined. Apolipoprotein E-deficient spontaneously hyperlipidemic mice underwent uninephrectomy (UNx) or sham operation (sham) followed by treatment with Ang II receptor antagonist losartan or hydralazine for 12 wk. While UNx did not increase the serum creatinine levels, BP and lipids were higher in UNx mice than in age-matched sham controls with intact kidneys. UNx caused a dramatic increase in the extent and the number of atherosclerotic lesions together with greater macrophage-positive area and more disruption in the elastin component of the extracellular matrix versus sham. Ang II antagonism dramatically decreased the UNx-induced acceleration in atherosclerosis in association with decreased macrophage content, linked to decreased macrophage migration in vitro with losartan but not with hydralazine. Aortae of mice treated with Ang II antagonism had fewer elastin breaks together with less immunostaining for the powerful elastolytic enzyme cathepsin S. None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in BP. These findings support an important role for endogenous Ang II in accelerated atherosclerosis in renal dysfunction and offer a therapeutic intervention with particular benefit in this setting through mechanisms that include reduced vascular macrophage infiltration and preservation of the elastin component of extracellular matrix.

Original languageEnglish (US)
Pages (from-to)433-441
Number of pages9
JournalJournal of the American Society of Nephrology
Volume17
Issue number2
DOIs
StatePublished - Feb 2006
Externally publishedYes

Fingerprint

Angiotensin Receptors
Angiotensin II
Kidney
Hydralazine
Elastin
Atherosclerosis
Macrophages
Losartan
cathepsin S
Extracellular Matrix
Angiotensin Receptor Antagonists
Apolipoproteins E
Blood Vessels
Aorta
Creatinine
Cardiovascular Diseases
Placebos
Lipids
Enzymes
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Suganuma, E., Zuo, Y., Ayabe, N., Ma, J., Babaev, V. R., Linton, M. F., ... Kon, V. (2006). Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. Journal of the American Society of Nephrology, 17(2), 433-441. https://doi.org/10.1681/ASN.2005080883

Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. / Suganuma, Eisuke; Zuo, Yiqin; Ayabe, Nobuhiko; Ma, Ji; Babaev, Vladimir R.; Linton, MacRae F.; Fazio, Sergio; Ichikawa, Iekuni; Fogo, Agnes B.; Kon, Valentina.

In: Journal of the American Society of Nephrology, Vol. 17, No. 2, 02.2006, p. 433-441.

Research output: Contribution to journalArticle

Suganuma, E, Zuo, Y, Ayabe, N, Ma, J, Babaev, VR, Linton, MF, Fazio, S, Ichikawa, I, Fogo, AB & Kon, V 2006, 'Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction', Journal of the American Society of Nephrology, vol. 17, no. 2, pp. 433-441. https://doi.org/10.1681/ASN.2005080883
Suganuma, Eisuke ; Zuo, Yiqin ; Ayabe, Nobuhiko ; Ma, Ji ; Babaev, Vladimir R. ; Linton, MacRae F. ; Fazio, Sergio ; Ichikawa, Iekuni ; Fogo, Agnes B. ; Kon, Valentina. / Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. In: Journal of the American Society of Nephrology. 2006 ; Vol. 17, No. 2. pp. 433-441.
@article{a7c38095b4f04530b3b9ace68bd8b249,
title = "Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction",
abstract = "Angiotensin II (Ang II) increases atherosclerotic cardiovascular disease. Renal damage that is characterized by activation of Ang II markedly potentiates the risk for atherosclerosis, even in the setting of subtle renal impairment. Therefore, whether antagonism of Ang II actions can modify atherosclerosis in a model of mild renal impairment was examined. Apolipoprotein E-deficient spontaneously hyperlipidemic mice underwent uninephrectomy (UNx) or sham operation (sham) followed by treatment with Ang II receptor antagonist losartan or hydralazine for 12 wk. While UNx did not increase the serum creatinine levels, BP and lipids were higher in UNx mice than in age-matched sham controls with intact kidneys. UNx caused a dramatic increase in the extent and the number of atherosclerotic lesions together with greater macrophage-positive area and more disruption in the elastin component of the extracellular matrix versus sham. Ang II antagonism dramatically decreased the UNx-induced acceleration in atherosclerosis in association with decreased macrophage content, linked to decreased macrophage migration in vitro with losartan but not with hydralazine. Aortae of mice treated with Ang II antagonism had fewer elastin breaks together with less immunostaining for the powerful elastolytic enzyme cathepsin S. None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in BP. These findings support an important role for endogenous Ang II in accelerated atherosclerosis in renal dysfunction and offer a therapeutic intervention with particular benefit in this setting through mechanisms that include reduced vascular macrophage infiltration and preservation of the elastin component of extracellular matrix.",
author = "Eisuke Suganuma and Yiqin Zuo and Nobuhiko Ayabe and Ji Ma and Babaev, {Vladimir R.} and Linton, {MacRae F.} and Sergio Fazio and Iekuni Ichikawa and Fogo, {Agnes B.} and Valentina Kon",
year = "2006",
month = "2",
doi = "10.1681/ASN.2005080883",
language = "English (US)",
volume = "17",
pages = "433--441",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction

AU - Suganuma, Eisuke

AU - Zuo, Yiqin

AU - Ayabe, Nobuhiko

AU - Ma, Ji

AU - Babaev, Vladimir R.

AU - Linton, MacRae F.

AU - Fazio, Sergio

AU - Ichikawa, Iekuni

AU - Fogo, Agnes B.

AU - Kon, Valentina

PY - 2006/2

Y1 - 2006/2

N2 - Angiotensin II (Ang II) increases atherosclerotic cardiovascular disease. Renal damage that is characterized by activation of Ang II markedly potentiates the risk for atherosclerosis, even in the setting of subtle renal impairment. Therefore, whether antagonism of Ang II actions can modify atherosclerosis in a model of mild renal impairment was examined. Apolipoprotein E-deficient spontaneously hyperlipidemic mice underwent uninephrectomy (UNx) or sham operation (sham) followed by treatment with Ang II receptor antagonist losartan or hydralazine for 12 wk. While UNx did not increase the serum creatinine levels, BP and lipids were higher in UNx mice than in age-matched sham controls with intact kidneys. UNx caused a dramatic increase in the extent and the number of atherosclerotic lesions together with greater macrophage-positive area and more disruption in the elastin component of the extracellular matrix versus sham. Ang II antagonism dramatically decreased the UNx-induced acceleration in atherosclerosis in association with decreased macrophage content, linked to decreased macrophage migration in vitro with losartan but not with hydralazine. Aortae of mice treated with Ang II antagonism had fewer elastin breaks together with less immunostaining for the powerful elastolytic enzyme cathepsin S. None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in BP. These findings support an important role for endogenous Ang II in accelerated atherosclerosis in renal dysfunction and offer a therapeutic intervention with particular benefit in this setting through mechanisms that include reduced vascular macrophage infiltration and preservation of the elastin component of extracellular matrix.

AB - Angiotensin II (Ang II) increases atherosclerotic cardiovascular disease. Renal damage that is characterized by activation of Ang II markedly potentiates the risk for atherosclerosis, even in the setting of subtle renal impairment. Therefore, whether antagonism of Ang II actions can modify atherosclerosis in a model of mild renal impairment was examined. Apolipoprotein E-deficient spontaneously hyperlipidemic mice underwent uninephrectomy (UNx) or sham operation (sham) followed by treatment with Ang II receptor antagonist losartan or hydralazine for 12 wk. While UNx did not increase the serum creatinine levels, BP and lipids were higher in UNx mice than in age-matched sham controls with intact kidneys. UNx caused a dramatic increase in the extent and the number of atherosclerotic lesions together with greater macrophage-positive area and more disruption in the elastin component of the extracellular matrix versus sham. Ang II antagonism dramatically decreased the UNx-induced acceleration in atherosclerosis in association with decreased macrophage content, linked to decreased macrophage migration in vitro with losartan but not with hydralazine. Aortae of mice treated with Ang II antagonism had fewer elastin breaks together with less immunostaining for the powerful elastolytic enzyme cathepsin S. None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in BP. These findings support an important role for endogenous Ang II in accelerated atherosclerosis in renal dysfunction and offer a therapeutic intervention with particular benefit in this setting through mechanisms that include reduced vascular macrophage infiltration and preservation of the elastin component of extracellular matrix.

UR - http://www.scopus.com/inward/record.url?scp=33645458374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645458374&partnerID=8YFLogxK

U2 - 10.1681/ASN.2005080883

DO - 10.1681/ASN.2005080883

M3 - Article

C2 - 16371432

AN - SCOPUS:33645458374

VL - 17

SP - 433

EP - 441

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 2

ER -